Two cases were reported in women who were fully vaccinated: sequencing showed that both were infected with the mutant virus, although the infection was related to the virus of interest but with a different mutation.
He is discussing reports of two Covid-19 cases in two fully vaccinated women.Introduced in detail New England Journal of MedicineThese two episodes were found in more than 400 people who received a second dose of Pfizer-BionTech or Moderna more than two weeks before the diagnosis of Covid-19.
Covid variants can pierce vaccines
Both women developed mild forms of Covid-19: the first patient, a healthy 51-year-old woman with no risk factors for severe Covid-19, received the first dose of Moderna vaccine on January 21, 2021 , Received the vaccine for the second time in February. 19 March 10 (19 days after recall), the woman developed sore throat, congestion and headache, and tested positive for coronavirus. Her symptoms gradually disappeared within a week. The second patient is a 65-year-old woman who is healthy and has no risk factors for severe Covid-19. She received the first dose of Pfizer’s BioNtech vaccine on January 19 and the second dose on February 9. The woman showed fatigue, sinus congestion and headache on March 16. On March 17, 36 days after vaccination, The test result of Sars-Cov-2 was positive. Even in his case, the symptoms gradually stabilized and began to relieve on March 20.
“Although there is evidence that in Patient 1, the first dose of the vaccine produced a strong antibody response to the viral protein Spike, but a saliva-based PCR test found an infection 19 days after the second dose- Point out that scholars from Rockefeller University in New York have reported these two cases -The test was also positive for the infection of patient 2, who had completed the vaccination 36 days ago.”
The obtained viral genome sequencing results show A series of mutations Compared with the SARS-Cov-2 version originally discovered in Wuhan, China, it includes some changes that may be considered potentially clinically significant, although in both cases the infection is caused by the relevant variant But different from the concerns -English variant B.1.1.7 and New York variant B.1.526. “In patient 1 -Researcher designation- These mutations include E484K (which confers resistance to the normally induced class of neutralizing antibodies) and D615G.In patient 2, these mutations included D614G and S477N instead of“.
In detail, certain mutations (T95I, del144, E484K, A570D, D614G, P681H, and D796H) in the virus strain that infects patient 1 are shared with mutation B.1.526 (T95I, E484K, and D614G). Three further substitutions were identified in the virus that infected patient 2 (among which mutations T95I, G142V and del144, F220I, R190T, R237K, R246T and D614G were detected).
The researchers also further tested the serum sample obtained from patient 1 to measure its efficacy against the parental virus, the E484K mutant virus and the B.1.526 mutant virus. “We found that the serum is equally effective against each virus, which indicates that the antibody response of patient 1 recognized these variants, but it is still the case Not enough to prevent sudden infectionScholars added that, however, it is too early to draw conclusions on which variants are most likely to be infected after vaccination.
On the other hand, although both of these conditions should not be regarded as the cause of the alarm (“Of course, the patient does not need to be hospitalized -New York City Rockefeller University professor and senior physician Dr. Robert Darnell (Robert Darnell) explained, co-author of the study. They have a Covid case at home“), the US Centers for Disease Control and Prevention (CDC) is the first member of the federal agency responsible for public health affairs in the United States. So far, the number of infections recorded in the vaccinated population is about 5800 out of 77 million, which is equivalent to 0.008% ”Data to support the maintenance of mitigation strategies, including screening of asymptomatic people, public release and analysis of vaccine and infection databases, and SARS-CoV-2 rapid sequencingConcluding scholars.